Skip to content
DataLookout
Menu

CNRIDNCT05154370

China National Registry of Neuro-Inflammatory Diseases

StatusUnknown
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Jul 2023); last known: Recruiting
  2. Minor Study description expanded, about 2 words
    • Study title shortened, about 2 words
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Annual relapse rate (ARR) between baseline and follow-up in patients with IDD
Timeframe: baseline up to 5 years
Change in EDSS scores of patients with IDD between baseline and follow-up over time
Timeframe: baseline, Month 6, Month12, Month18, Month24, Month30, Month36, Month42, Month48, Month54, Month60

Secondary (12)

The brain structural change over time between the baseline MRI and the follow-up MRIs
The spinal cord change over time between the baseline MRI and the follow-up MRIs.
Change of the central vein sign at 7T MRI.
Change of rim of iron at 7T MRI.
Change in High-contrast Letter Acuity (HCLA) over time at baseline and during follow-up in patients with IDD
Show 7 moreShow less
Change in Low-contrast Letter Acuity (LCLA) over time at baseline and during follow-up in patients with IDD
Percentage Change in Spectral-domain Optical Coherence Tomography (SD-OCT) Average Retinal Nerve Fiber Layer (RNFL) Thickness at baseline and every year.
Percentage change in SD-OCT Average Retinal Ganglion Cell Layer/Inner Plexiform Retinal Layer (RGCL/IPL) every year.
Changes in cognitive function of patients with IDD at baseline and over time during follow-up
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
NF-L level in serum.
Determination of serum autoimmune antibodies

Arms and interventions

MS/CIS

Diagnosis of MS and CIS based on the 2017 McDonald MS diagnostic criteria.

ADEM

Diagnosis of ADEM based on the 2012 IPMSSG diagnostic criteria for ADEM

MOGAD

Diagnosis of MOGAD based on the 2020 Chinese Expert Consensus.

NMOSD

diagnosis of NMOSD according to 2015 International Panel for Neuromyelitis Optica Diagnosis criteria.

Drugs: Intravenous steroid

Sites

1 site in 1 country

  • Beijing Tiantan HospitalBeijing, Beijing Municipality, China